MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Clinical Trials

5.0k

Active:1712
Completed:2475

Trial Phases

6 Phases

Early Phase 1:2
Phase 1:2253
Phase 2:662
+3 more phases

Drug Approvals

69

SFDA:52
NMPA:17

Drug Approvals

Elranatamab Injection

Product Name
易瑞欧
Approval Number
国药准字SJ20250011
Approval Date
Mar 4, 2025
NMPA

Elranatamab Injection

Product Name
易瑞欧
Approval Number
国药准字SJ20250010
Approval Date
Mar 4, 2025
NMPA

Rimegepant Sulfate Orally Disintegrating Tablets

Product Name
乐泰可
Approval Number
国药准字HJ20240004
Approval Date
Jan 23, 2024
NMPA

Ritlecitinib Tosylate Capsules

Product Name
乐复诺
Approval Number
国药准字HJ20230118
Approval Date
Oct 18, 2023
NMPA

Azithromycin for injection

Product Name
希舒美
Approval Number
国药准字HJ20130831
Approval Date
Sep 22, 2023
NMPA

Azithromycin for Injection

Product Name
希舒美
Approval Number
国药准字HJ20130830
Approval Date
Sep 22, 2023
NMPA

Azithromycin for Injection

Product Name
希舒美
Approval Number
国药准字HJ20140685
Approval Date
Sep 22, 2023
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220031
Approval Date
Apr 8, 2022
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220029
Approval Date
Apr 8, 2022
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220030
Approval Date
Apr 8, 2022
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (3899 trials with phase data)• Click on a phase to view related trials

Phase 1
2253 (57.8%)
Phase 3
674 (17.3%)
Phase 2
662 (17.0%)
Phase 4
233 (6.0%)
Not Applicable
71 (1.8%)
phase_1_2
3 (0.1%)
Early Phase 1
2 (0.1%)
phase_2_3
1 (0.0%)

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Not Applicable
Not yet recruiting
Conditions
Pulmonary Hypertension
Interventions
First Posted Date
2025-07-18
Last Posted Date
2025-07-18
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT07073820

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

Completed
Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
Drug: nirmatrelvir-ritonavir
First Posted Date
2025-07-18
Last Posted Date
2025-07-18
Lead Sponsor
Pfizer
Target Recruit Count
84584
Registration Number
NCT07072793
Locations
🇺🇸

Pfizer New York, New York, New York, United States

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Phase 3
Not yet recruiting
Conditions
Severe Alopecia Areata
Interventions
Drug: Ritlecitinib higher dose
Drug: Ritlecitinib lower dose
First Posted Date
2025-06-19
Last Posted Date
2025-06-19
Lead Sponsor
Pfizer
Target Recruit Count
140
Registration Number
NCT07029828

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Phase 3
Not yet recruiting
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Hormone Sensitive Prostate Cancer
Prostate Cancer
Cancer of the Prostate
Interventions
First Posted Date
2025-06-19
Last Posted Date
2025-07-14
Lead Sponsor
Pfizer
Target Recruit Count
1000
Registration Number
NCT07028853
Locations
🇺🇸

Arizona Urology Specialists (AUS)-Professional Park, Tucson, Arizona, United States

🇺🇸

Arizona Urology Specialist, Tucson, Arizona, United States

🇨🇳

Nantong Tumor Hospital, Nantong, Jiangsu, China

and more 11 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 636
  • Next

News

Roche Explores Direct-to-Consumer Drug Sales Model to Reduce US Patient Costs

Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.

RedHill Biopharma Receives FDA Approval for Groundbreaking MAP-Targeted Crohn's Disease Study

RedHill Biopharma received positive FDA feedback for the first-ever clinical study targeting Mycobacterium avium subspecies paratuberculosis (MAP) infected Crohn's disease patients with RHB-204.

Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes

A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.

BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.

Sarepta Therapeutics Implements $400 Million Cost-Cutting Plan Amid Regulatory Challenges for Gene Therapy

Sarepta Therapeutics announced a $400 million annual cost-savings initiative in July 2025, including a 36% workforce reduction of 500 employees to achieve financial sustainability through 2027.

Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy

Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.

Oxford BioDynamics' EpiSwitch Biomarkers Show Promise in Pfizer Bladder Cancer Trial

Oxford BioDynamics' EpiSwitch blood-based biomarkers demonstrated strong correlation with immune profiles of patient tumors in Pfizer's JAVELIN Bladder 100 trial involving 496 bladder cancer patients.

Uniquity Bio Appoints Will Kane as CEO to Lead Anti-TSLP Therapy Through Phase III Development

Uniquity Bio has appointed Will Kane as President and CEO to advance solrikitug, a monoclonal antibody targeting TSLP, through completion of three Phase II trials and preparation for Phase III development.

ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries

ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.